225 related articles for article (PubMed ID: 37531660)
41. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
42. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract][Full Text] [Related]
43. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.
Jackow CM; McHam JB; Friss A; Alvear J; Reveille JR; Duvic M
J Invest Dermatol; 1996 Sep; 107(3):373-6. PubMed ID: 8751973
[TBL] [Abstract][Full Text] [Related]
44. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.
Lewis NE; Gao Q; Petrova-Drus K; Pulitzer M; Sigler A; Baik J; Moskowitz AJ; Horwitz SM; Dogan A; Roshal M
Cytometry B Clin Cytom; 2022 May; 102(3):189-198. PubMed ID: 35451196
[TBL] [Abstract][Full Text] [Related]
45. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
46. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the novel Sezary lymphoma cell line BKP1.
Boudjarane J; Essaydi A; Farnault L; Popovici C; Lafage-Pochitaloff M; Beaufils N; Berda-Haddad Y; Lacroix R; Nicolino-Brunet C; Le Treut T; Zattara H; Gabert J; Kahn-Perlès B; Costello R
Exp Dermatol; 2015 Jan; 24(1):60-2. PubMed ID: 25314094
[TBL] [Abstract][Full Text] [Related]
48. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
49. Using molecular biologic analysis of T-cell receptor gene rearrangements to stage cutaneous T-cell lymphoma.
Wood GS
Arch Dermatol; 1998 Feb; 134(2):221-3. PubMed ID: 9487215
[No Abstract] [Full Text] [Related]
50. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
51. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
52. Computational Flow Cytometry Accurately Identifies Sezary Cells Based on Simplified Aberrancy and Clonality Features.
Seheult JN; Weybright MJ; Jevremovic D; Shi M; Olteanu H; Horna P
J Invest Dermatol; 2024 Jul; 144(7):1590-1599.e3. PubMed ID: 38237727
[TBL] [Abstract][Full Text] [Related]
53. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
[TBL] [Abstract][Full Text] [Related]
54. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
55. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
56. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
57. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome.
Thangavelu M; Finn WG; Yelavarthi KK; Roenigk HH; Samuelson E; Peterson L; Kuzel TM; Rosen ST
Blood; 1997 May; 89(9):3371-7. PubMed ID: 9129044
[TBL] [Abstract][Full Text] [Related]
58. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
[TBL] [Abstract][Full Text] [Related]
59. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
60. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
Bunn PA; Foss FM
J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
